Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
The aim of this study is to evaluate the immunogenicity and safety of a novel DTaP-IPV-Hep B-PRP~T fully liquid combined hexavalent vaccine (study vaccine) administered at 2, 4, and 6 months of age compared to Sanofi Pasteur's DTaP-IPV//PRP~T combined vaccine (Pentaxim™) given at 2, 4, and 6 months of age and Hep B vaccine (Euvax B®) given at 1 and 6 months of age in South Korean infants that received a birth dose of Hep B and born to mothers documented to be serum anti-HBs Ag negative. Primary Objective - To demonstrate the non-inferiority in terms of seroprotection (Diphtheria, Tetanus, poliovirus types 1, 2, and 3, PRP-T, Hep B) and vaccine response for pertussis antigens (pertussis toxoid [PT] and filamentous haemagglutinin [FHA]) of Group A versus Group B, one month after the third dose of combined vaccines. Secondary Objectives: - To further study the immunogenicity of the two vaccination schemes, before the first dose and one month after the last dose of vaccines. - To study the safety after each and any dose of vaccines administered in the two vaccination schemes
Inclusion criteria
- Diphtheria,TETANUS,Pertussis,Haemophilus Influenzae Type b Infection,Poliomyelitis,Hepatitis B